Guardant Health, Inc. (GH)
- Previous Close
17.16 - Open
16.98 - Bid 17.31 x 500
- Ask 17.41 x 100
- Day's Range
16.77 - 17.52 - 52 Week Range
15.81 - 41.06 - Volume
288,988 - Avg. Volume
1,994,511 - Market Cap (intraday)
2.112B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-4.28 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.53
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
guardanthealth.com1,768
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GH
Performance Overview: GH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GH
Valuation Measures
Market Cap
2.09B
Enterprise Value
2.27B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.41
Price/Book (mrq)
13.16
Enterprise Value/Revenue
4.03
Enterprise Value/EBITDA
-5.25
Financial Highlights
Profitability and Income Statement
Profit Margin
-85.02%
Return on Assets (ttm)
-17.64%
Return on Equity (ttm)
-438.12%
Revenue (ttm)
563.95M
Net Income Avi to Common (ttm)
-479.45M
Diluted EPS (ttm)
-4.28
Balance Sheet and Cash Flow
Total Cash (mrq)
1.17B
Total Debt/Equity (mrq)
853.12%
Levered Free Cash Flow (ttm)
-176.88M
Research Analysis: GH
Company Insights: GH
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GH
Analyst Report: Guardant Health, Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice TargetAnalyst Report: Guardant Health, Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice TargetAnalyst Report: Guardant Health, Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice TargetAnalyst Report: Guardant Health, Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice Target